Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review

Abstract Background Programmed cell death protein 1 (PD-1) checkpoint inhibitors such as pembrolizumab are novel therapeutics used to treat various advanced malignancies. Immune-related adverse events are common, among the most serious of these toxicities is hemophagocytic lymphohistiocytosis (HLH),...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Chongya Zhai, Xuanhong Jin, Liangkun You, Na Yan, Jie Dong, Sai Qiao, Yuhong Zhong, Yu Zheng, Hongming Pan
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2024-01-01
Schriftenreihe:	BMC Geriatrics
Schlagworte:	Hemophagocytic lymphohistiocytosis Pembrolizumab Immune-related adverse event
Online-Zugang:	https://doi.org/10.1186/s12877-023-04625-3
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!